Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8000403 | 0.92 | MAOB (0.57) | HDAC8PTPN1SMN1; SMN2SMPD1HDAC1 | |
| SCHEMBL6702501 | 0.92 | PTPN1 (0.57) | MTNR1AMTNR1BHDAC8PTPN1SMN1; SMN2 | |
| SCHEMBL19712578 | 0.89 | MAOB (0.55) | MTNR1AMTNR1BPTPN1NPC1RAB9A | |
| SCHEMBL18066376 | 0.88 | ALDH1A1 (0.54) | HDAC8PTPN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28205234 | 0.86 | MTNR1A (0.56) | MTNR1AMTNR1BHDAC8NPC1RAB9A | |
| SCHEMBL4627636 | 0.86 | NPC1 (0.60) | MTNR1AMTNR1BHDAC8NPC1RAB9A | |
| SCHEMBL6195352 | 0.86 | MAOB (0.55) | HDAC8PTPN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4363943 | 0.86 | MAOB (0.57) | PTPN1NPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL18066374 | 0.85 | PTPN1 (0.51) | HDAC8PTPN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18066371 | 0.85 | PTPN1 (0.51) | MTNR1AMTNR1BPTPN1KDM4EMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3098224-B1 | PYRANOCHROMENYL PHENOL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME OR INFLAMMATORY DISEASE | GLACEUM INC (KR) | 2019-01-30 | — | — | EP | disclosed |
| US-9783551-B2 | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | Glaceum Inc. (KR) | 2017-10-10 | — | — | US | disclosed |
| EP-3098224-A1 | PYRANOCHROMENYL PHENOL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME OR INFLAMMATORY DISEASE | Glaceum, Inc. (KR) | 2016-11-30 | — | — | EP | disclosed |
| US-20160272650-A1 | PYRANOCHROMENYL PHENOL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME OR INFLAMMATORY DISEASE | ERUM BIOTECHNOLOGIES, INC. (KR) | 2016-09-22 | — | — | US | disclosed |
| CN-105849111-A | Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease | 依如睦生物科技株式会社 | 2016-08-10 | — | — | CN | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272650-A1 | PYRANOCHROMENYL PHENOL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME OR INFLAMMATORY DISEASE | NLRP3, PPARD, PPARG | MTNR1A 598/4885MTNR1B 1170/4885HDAC8 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.